Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement prior to its Expiration upon notice to COH without cause, effective no fewer than 90 days following the date of such notice.
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement in its entirety for any reason upon ninety (90) days prior written notice to Licensor. Upon termination in accordance with this Section 7.2, the licenses granted by Licensor pursuant to Article 2 shall terminate in its entirety. Licensee shall remain obligated for all payments due at the time of such notice and for any continuing obligations otherwise surviving and owed under this Agreement pursuant to Section 7.9.
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement prior to its expiration upon notice to Caltech without cause, effective no fewer than ninety (90) days following the date of such notice.
Termination at Will by Licensee. Licensee may terminate this Agreement by giving DUKE written notice at least two (2) months prior to such termination. Upon termination, Licensee must terminate the manufacture, use, practice, and Sale of Licensed Products and Licensed Services. It is understood that Licensee remains responsible for the timely payment of all amounts due DUKE under this Agreement through the effective date of the termination.
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement in its entirety or on a Commercial License-by-Commercial License basis for any reason upon ninety (90) days prior written notice to Licensor. Upon termination in accordance with this Section 7.2, the licenses granted by Licensor pursuant to Article 2 shall terminate with regard to each Target for which a Commercial License has been terminated as provided above, or for all Targets, if this Agreement is terminated in its entirety. Licensee shall remain obligated for all payments due at the time of such notice and for any continuing obligations otherwise surviving and owed under this Agreement pursuant to Section 7.9 with regard to each terminated Commercial License and with regard to Targets for which the Commercial License has not been terminated by Licensee pursuant to this Section. [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND FILED SEPARATELY WITH THE COMMISSION
Termination at Will by Licensee. At any time after both (a) Licensee has obtained Regulatory Approval for a Licensed Product in Mainland China in relapse/refractory AML (and paid to Agios all applicable milestone payments associated with such Regulatory Approval) and (b) the last patient has been enrolled in the [**] Trial (the “Terminable Date”), Licensee may terminate this Agreement for any or no reason upon giving twelve (12) months’ notice to Agios (which notice may not be provided until after the Terminable Date has occurred); provided, however, that Licensee may provide a notice of termination pursuant to this Section 14.02 (Termination at Will by Licensee) earlier than the Terminable Date if Licensee has given Agios notice of its intent to terminate this Agreement following an applicable Change in Control pursuant to Section 16.03(a)(ii). Simultaneously with providing Agios a notice of termination under this Section 14.02 (Termination at Will by Licensee), Licensee shall provide to Agios a list of all Local Studies that are ongoing at such time. During the twelve (12) month period after Licensee notifies Agios that Licensee is terminating this Agreement under this Section 14.02 (Termination at will by Licensee), Licensee shall continue to be subject to all obligations, including all payment and diligence obligations, under this Agreement; provided, however, that, at any time during such twelve (12) month period, Agios may, by providing [**] prior written notice to Licensee, assume, for the remainder of such twelve (12) month period, all Development of Licensed Products in the Field in the Territory, other than any ongoing Local Studies that Agios elects not to pursue (each such Local Study a “Rejected Local Study”), in which case Licensee shall (a) promptly wind down all Rejected Local Studies in compliance with all applicable Laws at Licensee’s sole expense and (b) within [**] days after receiving any invoice therefor, reimburse Agios for the lesser of (i) [**] percent ([**]%) of all Out-of-Pocket Costs incurred by Agios or any of its Affiliates in Developing Licensed Products in the Field in the Territory (or Manufacturing Ivosidenib Materials or Licensed Products for such Development) during such remainder of such twelve (12) month period and (ii) the costs budgeted for the activities set forth in the then-current Development Plan for the remainder of such twelve (12) month period. If any Rejected Local Study continues beyond the effective date of termination under this Section ...
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement prior to its Expiration upon notice to NanoMab without cause, effective no fewer than ninety (90) days following the date of such notice.
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement at will, with or without cause, upon ninety (90) days *The asterisk denotes that confidential portions of this exhibit have been omitted in reliance on Rule 24b-2 of the Securities Exchange Act of 1934. The confidential portions have been submitted separately to the Securities and Exchange Commission. prior written notice to Licensor, provided that such termination shall be effective no earlier than the first anniversary of the date upon which Licensee made the last payment to Licensor under Section 5.1(i) below.
Termination at Will by Licensee. Prior to making the First Commercial Sale of a Licensed Product in the Territory, Licensee shall have the right to terminate this Agreement upon [***] prior written notice to Allergan.
Termination at Will by Licensee. Licensee shall have the right to terminate this Agreement in its entirety or on a Commercial License-by-Commercial License basis for any reason upon [***] prior written notice to Licensor. Upon termination in accordance with this Section 7.2, the licenses granted by Licensor pursuant to Article 2 shall terminate with regard to each Target for which a Commercial License has been terminated as provided above, or for all Targets, if this Agreement is terminated in its entirety. Licensee shall remain obligated for all payments due at the time of such notice and for any continuing obligations otherwise surviving and owed under this Agreement pursuant to Section 7.10 with regard to each terminated Commercial License and with regard to Targets for which the Commercial License has not been terminated by Licensee pursuant to this Section. [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Copy
